- US Specialty Formulations (USSF) is expanding its Lehigh Valley biopharma facility in Allentown with a $15 million investment, adding over 100 jobs.
- The expansion will significantly increase clean room production capacity and is expected to be completed by the end of 2025.
US Specialty Formulations (USSF) has announced a $15 million expansion of its Lehigh Valley biopharma facility in Allentown, Pennsylvania. The expansion is set to create more than 100 jobs and will enhance the company’s ability to undertake larger projects for both new and existing clients.
The expansion will introduce new clean room suites and state-of-the-art automated packaging and product inspection equipment. Once completed by the end of 2025, the expansion will more than double USSF’s clean room production capacity, providing a controlled environment essential for the production of sterile injectables, including small molecules, botanicals, and vaccines.
Established in 2013, USSF, co-founded by Dr. Kyle Flanigan, CEO, and Dr. Garry Morefield, COO, initially built its first certified clean room at the Ben Franklin Technical Incubator. This latest expansion marks the company’s third generation of clean rooms, incorporating cGMP standards and advanced quality control measures.
“This expansion is a transformative step for USSF,” said Dr. Flanigan. “By investing in cutting-edge technology and streamlining our manufacturing processes, we are raising the bar for ourselves and reaffirming our commitment to delivering innovative pharmaceutical solutions that reduce the risk profile of new drug development or contract manufacturing and ultimately improve patient lives. This expansion empowers our dedicated team to serve our partners and clients worldwide more effectively.”
US Specialty Formulations provides a range of services, including drug research and development, contract manufacturing, private label formulations, and packaging. The company is also known for pioneering QYNDR, an oral vaccine platform, and the first self-administered drinkable vaccine, which completed a successful Phase I clinical trial in 2023.
Overview of outsourcing trends 
